[go: up one dir, main page]

EP4493213A1 - Système d'administration de gène hsv persistant - Google Patents

Système d'administration de gène hsv persistant

Info

Publication number
EP4493213A1
EP4493213A1 EP23716131.0A EP23716131A EP4493213A1 EP 4493213 A1 EP4493213 A1 EP 4493213A1 EP 23716131 A EP23716131 A EP 23716131A EP 4493213 A1 EP4493213 A1 EP 4493213A1
Authority
EP
European Patent Office
Prior art keywords
hsv
vector
fuson
glycoprotein
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23716131.0A
Other languages
German (de)
English (en)
Inventor
Shaun ZHANG
Xinping Fu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Houston System
Original Assignee
University of Houston System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Houston System filed Critical University of Houston System
Publication of EP4493213A1 publication Critical patent/EP4493213A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16661—Methods of inactivation or attenuation
    • C12N2710/16664—Methods of inactivation or attenuation by serial passage

Definitions

  • This invention relates to non-replicating herpes simplex virus (HSV) based gene delivery vectors for delivering transgenes (e.g., a therapeutic gene) which are more resistant to neutralization and phagocytosis by immune systems, and methods for their preparation and treatment of disorders and diseases (such as those related to gene expression) with them.
  • HSV herpes simplex virus
  • Gene therapy has many potential clinical applications for treating a variety of diseases such as genetic diseases, autoimmune diseases, and cancer.
  • the success of gene therapy heavily relies on the availability of gene delivery vectors, such as viral vectors.
  • An ideal gene delivery vector can deliver the therapeutic genes efficiently to body tissues and ensure that the delivered therapeutic genes can stay in the tissue long-term.
  • the efficacy of viral vectors is often diminished by the host’s various defense mechanisms in the body.
  • anti -HSV neutralizing antibodies bind to introduced viral particles, such as herpes simplex virus (HSV) particles.
  • HSV herpes simplex virus
  • the neutralizing antibodies can diminish gene transuduction efficiency by several mechanisms. First, they prevent the virus from infecting cells. Second, they can bind to the transduced cells, leading to their destruction eitherby the host’s antibody-dependent cellular phagocytosis (ADCP) or by activation of complement system for the formation membrane attack complex (MAC) (Huber et al., 2001; Tay, Wiehe, and Pollara, 2019; Xie, Jane-Wit, and Pober, 2020).
  • ADCP antibody-dependent cellular phagocytosis
  • MAC membrane attack complex
  • the anti-HSV neutralizing antibodies are found to be mainly targeted at two of the virus-encoded glycoproteins - glycoprotein D (gD) and gB (Cairns et al., 2015; Cairns et al., 2014). Both gD and gB contain many neutralizing epitopes, presenting at diverse orders of immunodominant hierarchy in different individuals (Bender et al., 2007). Overall, these epitopes are well-conserved among infected individuals and/or different species (Eing, Ktihn, and Braun, 1989). The studies have also indicated that HSV-2 is more difficult to neutralize than HSV-1 (Silke Heilingloh et al., 2020).
  • NK cells Natural killer cells
  • the viral glycoprotein E (gE) is known to bind to IgG (Dubin et al., 1994).
  • gE viral glycoprotein E
  • Recent studies have shown that NK cells can recognize HSV or HSV infected cells via the binding of the surface CD 16 activating receptor with the Fc region in IgG bound to gE (Dai and Caligiuri, 2018).
  • U.S. Pat. Pub. No. 2012/0301506 and U.S. Patent Nos. 8,986,672 and 10,039,796 disclose modified HSV-2 and their usage in treating malignant tumors.
  • U.S. Patent Publication No. 2019/0267845 describes a HSV vector that does not express HSV genes in non-complementing cells and which comprises a genome comprising one or more transgenes, wherein the vector is capable of expression of a transgene for at least 28 days in noncomplementing cells.
  • U.S. Patent Publication No. 2018/0148711 discloses HSV-based genome editing vectors. [0013] Verlengia et al., Scz 2017 May 4, 7(l):1507, doi: 10.1038/s41598-017-01635-1, describes engineered HSV vectors for transgene expression in the central nervous system.
  • HSV vectors can deliver transgenes more efficiently and the delivered transgene could persist longer by passaging the HSV vectors with immune sera having elevated levels of anti-HSV antibodies and/or by including an extracellular CD47 domain (such as an extracellular human CD47 domain) in the membrane envelope. It was unexpectedly found that passaging of CD47-containing virus resulted in the near complete absence of gE from the viral particles. This allows the virus to escape from the NK cell- mediated antiviral mechanism. The insertion of the extracellular domain of CD47 into the N- terminus of gC was also found to enable the virus to escape neutralization by anti-HSV antibodies, even without passaging.
  • the HSV vectors described herein can be non-oncolytic and are non-toxic.
  • One embodiment of the present invention is a composition comprising a non-replicating herpes simplex virus (HSV) based gene delivery vector, wherein (i) the HSV-based vector comprises a transgene, and (ii) the HSV-based vector is prepared by passaging at least twice the HSV-based vector with immune sera having elevated levels of anti-HSV antibodies. In one embodiment, the passaging in the immune sera mutates neutralizing epitopes on glycoprotein B and glycoprotein D of the HSV-based vector.
  • the vector preferably also includes a promoter operably linked to the transgene.
  • the HSV-based vector is non-oncolytic. In another embodiment, the HSV-based vector is persistent.
  • the HSV-based vector can be HSV-1 or HSV-2.
  • a preferred HSV-based vector is HSV- 2.
  • the HSV-based vector can be an amplicon packaged into a HSV-1 or HSV-2 particle.
  • the HSV-based vector has a membrane envelope comprising glycoproteins, wherein at least one of the glycoproteins comprises an extracellular CD47 domain inserted into the N-terminus of a glycoprotein.
  • the glycoprotein may be selected from glycoprotein C, glycoprotein B, glycoprotein D, glycoprotein H, and glycoprotein L.
  • the membrane envelope includes a glycoprotein C having an extracellular CD47 domain inserted into its N-terminus.
  • the extracellular CD47 domain can be murine derived or human derived.
  • the extracellular CD47 domain can comprise amino acids 19-141 of murine CD47 (SEQ ID NO:1).
  • the extracellular CD47 domain can comprise amino acids 55-423 of human CD47 (SEQ ID NO:3).
  • the vector includes a genome encoding the CD47 domain.
  • the HSV-based vector is free or substantially free of gE.
  • the immune sera can be a mixture comprising rat sera and human sera that has elevated levels of anti-HSV antibodies.
  • the HSV-based vector is prepared by passaging at least two times (e.g., at least five times, or seven times) the HSV-based vector in the presence of rat sera having an elevated level of anti-HSV antibodies followed by passaging at least two times (e.g., at least five or ten times, or seventeen or twenty -three times) in the presence of a mixture of rat sera and at least one human serum having an elevated level of anti-HSV antibodies.
  • the composition comprises cerebrospinal fluid.
  • Another embodiment is a non-replicating HSV-based vector comprising a transgene, where the HSV-based vector has a membrane envelope comprising glycoproteins, wherein at least one of the glycoproteins comprises an extracellular CD47 domain inserted into the N- terminus of a glycoprotein.
  • the HSV-based vector has a membrane envelope comprising glycoproteins, wherein at least one of the glycoproteins comprises an extracellular CD47 domain inserted into the N-terminus of a glycoprotein.
  • the glycoprotein may be selected from glycoprotein C, glycoprotein B, glycoprotein D, glycoprotein H, and glycoprotein L.
  • the membrane envelope includes a glycoprotein C having an extracellular CD47 domain inserted into its N-terminus.
  • the extracellular CD47 domain can comprise amino acids 19-141 of CD47 (SEQ ID NO:1). Alternatively, the extracellular CD47 domain can comprise amino acids 55-423 of human CD47 (SEQ ID NO:3).
  • the HSV-based vector is free or substantially free of gE. In one preferred embodiment, the neutralizing epitopes on glycoprotein B and glycoprotein D of the HSV-based vector are mutated.
  • the vector preferably also includes a promoter operably linked to the transgene.
  • the HSV-based vector is non-oncolytic.
  • the HSV-based vector is persistent.
  • the vector includes a genome encoding the extracellular CD47 domain (e g., which may be murine or human derived).
  • Yet another embodiment is a method of preparing a composition comprising a nonreplicating herpes simplex virus (HSV)-based vector (such as an HSV-based vector described herein) comprising passaging at least twice the HSV-based vector comprising a transgene with immune sera that has elevated levels of anti-HSV antibodies.
  • HSV herpes simplex virus
  • the immune sera comprises mammalian anti-HSV antibodies.
  • the immune sera is a mixture comprising rat sera and human sera that has elevated levels of anti-HSV antibodies.
  • the method comprises passaging the HSV-based vector at least two times (e.g., at least five times, or seven times) in the presence of rat sera having an elevated level of anti-HSV antibodies followed by passaging at least once (e.g., at least two, five, or ten times, or seventeen or twenty-three times) in the presence of a mixture of rat sera and at least one human serum having an elevated level of anti-HSV antibodies.
  • Yet another embodiment is a method of treating a disease in a patient in need thereof comprising administering to the patient a composition described herein or a non-replicating HSV-based vector described herein.
  • the disease or disorder can be a neurological disease or disorder.
  • the disease or disorder is not an oncologic disease or disorder (e.g., the disease or disorder is not a cancer).
  • the composition or HSV-based vector can be systemically, intramuscularly, intrademally, subcutaneously, or parenterally administered or administered by intracerebroventricular or intraperitoneal injection.
  • the patient has been exposed to or vaccinated against HSV-1 and/or HSV-2, or has HSV-1 and/or HSV-2.
  • Yet another embodiment is a method of vaccinating a patient against a malignant or infectious disease comprising administering to the patient a composition described herein or a non-replicating HSV-based vector described herein.
  • the transgene is one useful for vaccinating a patient.
  • FIG. l is a bar chart showing differential sensitivity of trained and untrained FusOn-H2 to anti-HSV sera.
  • 1X10 4 untrained Fuson-H2 or trained FusOn-SS9 were mixed with either human or rat anti-HSV-2 sera at a final concentration of 1 :5. After 1 h incubation at 37°C, the solution was applied to Vero monolayer at a 12-well plate. The plaques were countered 48 h later after crystal violet staining.
  • FIG. 2A is a schematic illustration of inserting the CD47 encoding sequence into the HSV vector. It shows the insertion of an EGFP-Luc gene cassette (the transgene, which could be any therapeutic gene) and the CMVp-HAtag-CD47ECD into the backbone of an HSV vector (FusOn-H2) which was done through homologous recombination, with the left flanking (LF) sequence and the 3’ region of gC (from the transmembrane domain to the poly A) as the right flanking sequence.
  • LF left flanking
  • gC from the transmembrane domain to the poly A
  • CMVp cytomegalovirus immediate early promoter
  • LTR Rous Sarcoma long terminal repeats that contain the promoter region of this virus
  • GFP-Luc EGFP-luciferase fusion gene
  • HA HA tag
  • CD47 murine CD47 extracellular domain
  • gC the complete gC coding region.
  • LF the left flanking region of gC.
  • the recombinant viruses were identified by GFP expression and purified to homogeneity.
  • FIG. 2B is a schematic illustration of FusOn-Luc construction strategy. It shows FusOn- Luc, which contains the transgene only without CD47 (as a control virus), was constructed in a similar way, except that it does not contain the CD47 extracellular domain.
  • FIG 3 is a chart showing the comparison of FusOn-CD47 and FusOn-Luc for ability to transduce cells and to replicate in the presence of phagocytes. It is a comparison of virus yield with or without the presence of phagocytes. Vero cells in 12-well plates were infected with either virus at 0.1 pfu/cell without or with the presence of 200,000 splenocytes. Cells were harvested 48 h and the virus yield was determined by plaque assay. ⁇ p ⁇ 0.05 as compared with other three wells.
  • FIG. 4A is a chart showing the mean photon reading (i.e., the quantifty of Luc transgene expression) from daily IVIS imaging measurement, demonstrating that FusOn-CD47 can be more efficiently delivered and the transgene persists longer than FusOn-Luc by the systemic route of delivery (in this case, to the tumor tissues).
  • the tumor was established at the right flank of Balb/c mice by subcutaneous implantation of CT26 cells. Once tumor reached the approximate size of 8 mm in diameter, 2X10 6 pfu of either FusOn-CD47 or FusOn-Luc was given systemically.
  • FIG. 4B is a time-lapse of images of the transgene expression in typical mice days after systemic delivery of FusOn-CD47. It shows that the transgene can be more efficiently delivered by FusOn-CD47 than FusOn-Luc by the systemic route.
  • Tumor was established at the right flank of Balb/c mice by subcutaneous implantation of CT26 cells. Once tumor reached the approximate size of 8 mm in diameter, 2X10 6 pfu of either FusOn-CD47 or FusOn-Luc was given systemically. Animals were imaged daily starting on day 2 for luciferase expression.
  • FIG. 5 is a chart showing enhanced resistance of FusOn-CD47 to the neutralization effect by the anti-HSV sera after training. 1X10 4 untrained FusOn-CD47 or the trained FusOn-
  • CD47-SS24 (7 passages in the presence of rat sera and 17 passages in the presence of rat sera plus one human serum) were mixed with either human or rat anti-HSV-2 sera at a final concentration of 1 :5. After 1 h incubation at 37°C, the solution was applied to Vero monolayer at a 12-well plate. The plaques were countered 48 h later after crystal violet staining.
  • FIG. 6 is a chart showing trained FusOn-CD47 acquired additional resistance to anti- HSV immune sera.
  • 5X1O 3 untrained Fuson-CD47 or the same virus trained at different stage [serial selection 24 (FusOn-CD47-SS24), serial selection 49 (HR49, N2-N5 and N7-N8)] were mixed with an eight-human sera mixture at different dilutions.
  • the trained FusOn-H2 (FusOn- SS9) was also included in this experiment. After 1 h incubation at 37°C, the solution was applied to Vero monolayer at a 12-well plate. The plaques were countered 48 h later after crystal violet staining.
  • FIG. 7 is a bar chart showing that the insertion of CD47 can enhance the ability of the HSV vector to escape neutralizing antibodies.
  • Five hundred pfu of FusOn-CD47 and FusOn- Luc were incubated with anti-HSV-2 sera at the indicated dilution (1 :40 or 1 : 160) at 37°C for 1 hour before they were used to infect Vero cells in a 6-well plate. The same number of viruses was incubated with medium only as a control. The cells were stained with crystal violet 48 hours later for enumeration of viral plaques. The percentage of plaques was calculated by dividing the plaque number in the wells containing anti-HSV sera with those from the wells with the same virus without the anti-HSV sera (the controls). ⁇ indicates a p ⁇ 0.05 as compared with FusOn-Luc.
  • FIG. 8 is a time-lapse of images on the transgene expression in typical mice days after systemic delivery of FusOn-CD47, FusOn-Luc or FusOn-SD. It shows that FusOn-CD47, but not FusOn-Luc, could be sufficiently delivered by the systemic route, to mice that have preexisting anti-HSV immunity, and the passaging of FusOn-CD47 in sera containing anti-HSV antibodies (to generate FusOn-SD) further enhanced the ability of the virus to be delivered by systemically in these mice.
  • Balb/c mice were vaccinated with FusOn-H2 and then implanted with CT26 tumor cells at the right flank. Mice in separate groups were given with each of these three viruses via the tail vein at the dose of 1X10 7 pfu. Mice were imaged using an IVIS imager at the indicated days after virus injection.
  • FIG. 9A is is a bar chart showing the enzyme-linked immunosorbent assay (ELISA) on gE expression (via the absorbance at 450 nm) on FusOn-H2, FusOn-SD, and PBS (negative control) after incubating the viruses initially with mouse anti-HSV-2 gE (1 : 1000 dilution) and then with HPR-conjugated rabbit anti-mouse IgG (1 : 10,000 dilution).
  • ELISA enzyme-linked immunosorbent assay
  • FIG. 9B is a Western blot showing the absence of gE in FusOn-SD but not in FusOn- H2.
  • the viruses were first incubatedwith mouse anti-HSV-2 gE (1 : 1000 dilution) and then with HPR-conjugated rabbit anti-mouse IgG (1 : 10,000 dilution) for the Western blot detection.
  • FIG. 9C is a schematic illustration on the mechanism of NK cell recognition of HSV or HSV infected cells via gE.
  • HSVs herpes simplex viruses
  • HSV-based gene delivery vectors can thus be particularly useful for gene therapy for neurological disorders.
  • virus-based vectors the host’s antiviral immune mechanisms can often clear the viral vectors, thus limiting their efficiency in gene delivery. Both the host’s innate and acquired antiviral immunity can clear HSV-based vectors.
  • the major innate antiviral immune components are macrophages and natural killer cells (NK cells), and the main acquired antiviral immune component is the neutralizing antibodies.
  • gE can bind to IgG, which can be subsequently recognized by NK cells to kill cells transduced by HSV- based vectors, the absence of gE from the viral particles allows more efficient gene transduction by enabling the cells to escape from NK cell-mediated killing effect.
  • HSV-based gene delivery vectors are particularly useful for gene therapy applications in treating neurological disorders.
  • both innate and acquired antiviral mechanisms are major hurdles for HSV- based gene delivery vectors, comprising their gene delivery efficiency.
  • the invention disclosed here addresses these hurdles, allowing the viral vectors to be used more effectively, exemplarily, for their clinical application for gene therapy.
  • the term “Herpes Simplex Virus” or “HS V” as used herein refers to an enveloped, icosahedral, double-stranded DNA virus that infects mammals, including humans. Wild- type HSV infects and replicates in both terminally differentiated non-dividing cells and dividing cells.
  • the HSV vector can be a HSV-based genome editing vector, as described in U.S. Patent Publication No. 2018/0148711.
  • the HSV vector can also be a HSV vector that does not express toxic HSV genes in non-complementing cells and which comprises a genome comprising one or more transgenes as described in U.S. Patent Publication No. 2019/0276845.
  • HSV-2 persistent virus and “HSV-2 mutant” are used interchangeably herein.
  • cell membrane fusion and “fusion” as used herein refers to fusion of an outer membrane of at least two cells, such as two adjacent cells, for example.
  • enhanced fusogenic activity refers to an enhancement, increase, intensification, argumentation, amplification, or combination thereof of the cell membrane fusion.
  • Persistent refers to a viral infection characterized as those in which the virus is not cleared but remains in specific cells of infected individuals. Persistent infections may involve stages of both silent and productive infection without rapidly killing or even producing damage to the host cells.
  • vector refers to a carrier nucleic acid molecule into which a nucleic acid sequence can be inserted for introduction into a cell where it can be replicated.
  • the inserted nucleic acid sequence is referred to as “exogenous” either when it is foreign to the cell into which the vector is introduced or when it is homologous to a sequence in the cell but in a position within the host cell nucleic acid in which die sequence is ordinarily not found.
  • Viral vectors are encapsulated in viral proteins and capable of infecting cells.
  • a vector can be constructed standard recombinant techniques.
  • expression vector refers to any type of genetic construct comprising a nucleic acid coding for a RNA capable of being transcribed. In some cases, RNA molecules are then translated into a protein, polypeptide, or peptide. In other cases, these sequences are not translated, for example, in the production of antisense molecules or ribozymes.
  • Expression vectors can contain a variety of “control sequences,” which refer to nucleic acid sequences necessary for the transcription and possibly translation of an operably linked coding sequence in a particular host cell.
  • control sequences refer to nucleic acid sequences necessary for the transcription and possibly translation of an operably linked coding sequence in a particular host cell.
  • vectors and expression vectors may contain nucleic acid sequences that serve other functions as well and are described infra.
  • a “promoter” is a control sequence that is a region of a nucleic acid sequence at which initiation and rate of transcription are controlled. It may contain genetic elements at which regulatory proteins and molecules may bind, such as RNA polymerase and other transcription factors to initiate or regulate the temporal and spatial transcription of a nucleic acid sequence.
  • the phrases “operatively positioned,” “operably linked,” “under control,” and “under transcriptional control” mean that a promoter is in a correct functional location and/or orientation in relation to a nucleic acid sequence to control transcriptional initiation and/or expression of that sequence.
  • Exemplary non-limiting promoters include: a constitutive promoter, a tissue-specific promoter, a tumor-specific promoter, or an endogenous promoter under the control of an exogenous inducible element.
  • constitutive promoter refers to a promoter that drives expression of a gene or polynucleotide in a continuous temporal manner throughout the cell cycle.
  • a constitutive promoter may be cell or tissue-type specific as long as it operates in a continuous fashion throughout the cell cycle to drive the expression of the gene or polynucleotide with which it is associated.
  • Exemplary non-limiting constitutive promoters include: the immediate early cytomegalovirus (CMV) promoter, SV40 early promoter, RSV LTR, Beta chicken actin promoter, and HSV TK promoter.
  • the term “enhancer” refers to a cis-acting regulatory sequence involved in the control of transcriptional activation of a nucleic acid sequence.
  • patient refers to a mammal such as human or a domestic animal (e.g., a dog or cat). In a preferred embodiment, the patient or subject is a human.
  • serum refers to the fluid from blood that remains when hematocytes and clotting proteins are removed.
  • phrases “pharmaceutically” or “pharmacologically acceptable” as used herein refer to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, or human, as appropriate.
  • pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
  • unit dose refers to a physically discrete unit suitable for use in a subject, each unit containing a predetermined quantity of the therapeutic composition calculated to produce the desired response in association with its administration, i.e., the appropriate route and treatment regimen.
  • the invention may be utilized as a stand-alone therapy or in conjunction with another means of therapy, including pharmaceutical treatments and surgery.
  • the HSV vector comprises a transgene encoding a desired protein and in specific embodiments further comprises a regulatory sequence, such as a promoter.
  • the recombinant virus can be further comprised of some or all of the following components.
  • Vectors include but are not limited to, plasmids, cosmids, viruses (bacteriophage, animal viruses, and plant viruses), and artificial chromosomes (e.g., YACs).
  • Methods for the construction of engineered viruses and DNA vectors are known in the art. Generally these include Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press (1989) and the references cited therein. Virol ogical considerations are also reviewed in Coen D. M, Molecular Genetics of Animal Viruses in Virology, 2 nd Edition, B. N. Fields (editor), Raven Press, N.Y. (1990) and the references cited therein.
  • Expression vectors can contain a variety of “control sequences,” which refer to nucleic acid sequences necessary for the transcription and possibly translation of an operably linked coding sequence (such as a transgene) in a particular host cell.
  • control sequences refer to nucleic acid sequences necessary for the transcription and possibly translation of an operably linked coding sequence (such as a transgene) in a particular host cell.
  • DNA vectors, expression vectors, and viruses may contain nucleic acid sequences that serve other functions as well.
  • the HSV-based vector does not express ICPO, ICP4, ICP22, and ICP27 as immediate early genes.
  • ICPO interleukin-4, ICP24, and ICP27 as immediate early genes.
  • Such vectors can be prepared as described in U.S. Patent Publication No. 2019/0276845, which is hereby incorporated by reference.
  • the HSV vector can be an amplicon packaged into HSV-1 or HSV-2 particles.
  • HSV amplicons are unique gene delivery vectors. They are plasmid-based constructs that contain, in addition to the therapeutic gene(s), a copy of the HSV replication origin and a packaging signal. When co-delivered into cells together with a HSV virus as a helper, the amplicon constructs will be replicated (due to the presence of the replication origin) and then the replicated amplicon sequences will be packaged into viral particles (due to the presence of the packaging signal). The packaged amplicon possesses the same gene transduction property as the helper virus. All the HSV viruses described in this disclosure can be applied as a helper virus for HSV amplicon packaing for gene delivery.
  • a promoter generally comprises a sequence that functions to position the start site for RNA synthesis.
  • the best-known example of this is the TATA box, but in some promoters lacking a TATA box (e.g., the promoter for the mammalian terminal deoxynucleotidyl transferase gene and the promoter for the SV40 late genes) a discrete element overlying the start site itself helps to fix the place of initiation. Additional promoter elements regulate the frequency of transcriptional initiation. Typically, these are located in the region 30 to 110 bp upstream of the start site, although a number of promoters have been shown to contain functional elements downstream of the start site as well.
  • a promoter To bring a coding sequence “under the control of’ a promoter, one positions the 5' end of the transcription initiation site of the transcriptional reading frame “downstream” of (i.e., 3' of) the chosen promoter.
  • the “upstream” promoter stimulates transcription of the DNA and promotes expression of the encoded RNA.
  • the spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another.
  • the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline.
  • individual elements can function either cooperatively or independently to activate transcription.
  • a promoter may or may not be used in conjunction with an enhancer.
  • a promoter may be one naturally associated with a nucleic acid sequence, as may be obtained by isolating the 5' non-coding sequences located upstream of the coding segment and/or exon.
  • an enhancer may be one naturally associated with a nucleic acid sequence, located either downstream or upstream of that sequence.
  • certain advantages will be gained by positioning the coding nucleic acid segment under the control of a recombinant or heterologous promoter, which refers to a promoter that is not normally associated with a nucleic acid sequence in its natural environment.
  • a recombinant or heterologous enhancer refers to an enhancer not normally associated with a nucleic acid sequence in its natural environment.
  • promoters or enhancers may include promoters or enhancers of other genes, and promoters or enhancers isolated from any other virus, or prokaryotic or eukaryotic cell, and promoters or enhancers not “naturally occurring,” i .e., containing different elements of different transcriptional regulatory regions, and/or mutations that alter expression.
  • promoters that are most commonly used in recombinant DNA construction include the 0 lactamase (penicillinase), lactose and tryptophan (trp) promoter systems.
  • sequences may be produced using recombinant cloning and/or nucleic acid amplification technology, including PCR, in connection with the compositions disclosed herein (see U.S. Pat. Nos. 4,683,202 and 5,928,906).
  • control sequences which direct transcription and/or expression of sequences within non-nuclear organelles such as mitochondria, chloroplasts, and the like, can be employed as well.
  • promoter and/or enhancer that effectively directs the expression of the DNA segment in the organelle, cell type, tissue, organ, or organism chosen for expression.
  • the promoters employed may be constitutive, tissue-specific, inducible, and/or useful under the appropriate conditions to direct high level expression of the introduced DNA segment, such as is advantageous in the large-scale production of recombinant proteins and/or peptides.
  • the promoter may be heterologous or endogenous.
  • any promoter/enhancer combination may be used to drive expression.
  • Use of a T3, T7 or SP6 cytoplasmic expression system is another possible embodiment.
  • Eukaryotic cells can support cytoplasmic transcription from certain bacterial promoters if the appropriate bacterial polymerase is provided, either as part of the delivery complex or as an additional genetic expression construct.
  • tissue-specific promoters or elements as well as assays to characterize their activity, is well known to those of skill in the art.
  • Non-limiting examples of such regions include the human LTMK2 gene (Nomoto et al. (1999) Gene 236(2):259-271), the somatostatin receptor-2 gene (Kraus et al., (1998) FEBS Lett. 428(3): 165-170), murine epididymal retinoic acid-binding gene (Lareyre et al., (1999) J. Biol. Chem. 274(12):8282-8290), human CD4 (Zhao- Emonet et al., (1998) Biochem. Biophys.
  • a specific initiation signal also may be required for efficient translation of coding sequences. These signals include the ATG initiation codon or adjacent sequences. Exogenous translational control signals, including the ATG initiation codon, may need to be provided. One of ordinary skill in the art would readily be capable of determining this and providing the necessary signals. It is well known that the initiation codon must be “in-frame” with the reading frame of the desired coding sequence to ensure translation of the entire insert. The exogenous translational control signals and initiation codons can be either natural or synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements.
  • IRES elements are used to create multigene, or polycistronic, messages.
  • IRES elements are able to bypass the ribosome scanning model of 5' methylated Cap dependent translation and begin translation at internal sites.
  • IRES elements can be linked to heterologous open reading frames. Multiple open reading frames can be transcribed together, each separated by an IRES, creating polycistronic messages. By virtue of the IRES element, each open reading frame is accessible to ribosomes for efficient translation. Multiple genes can be efficiently expressed using a single promoter/enhancer to transcribe a single message (see U.S. Pat. Nos. 5,925,565 and 5,935,819).
  • Termination Signals will generally comprise at least one termination signal.
  • a “termination signal” or “terminator” is comprised of the DNA sequences involved in specific termination of an RNA transcript by an RNA polymerase. Thus, in certain embodiments a termination signal that ends the production of an RNA transcript is contemplated. A terminator may be necessary in vivo to achieve desirable message levels.
  • the terminator region may also comprise specific DNA sequences that permit site-specific cleavage of the new transcript so as to expose a polyadenylation site. This signals a specialized endogenous polymerase to add a stretch of about 200 A residues (poly A) to the 3' end of the transcript. RNA molecules modified with this polyA tail appear to be more stable and are translated more efficiently.
  • the terminator comprise a signal for the cleavage of the RNA, and that the terminator signal promote polyadenylation of the message.
  • the terminator and/or polyadenylation site elements can serve to enhance message levels and to minimize read through from the cassette into other sequences.
  • Terminators contemplated for use in the invention include any known terminator of transcription described herein or known to one of ordinary skill in the art, including but not limited to, for example, the termination sequences of genes, such as for example the bovine growth hormone terminator or viral termination sequences, such as for example the SV40 terminator.
  • the termination signal may be a lack of transcribable or translatable sequence, such as due to a sequence truncation.
  • polyadenylation signal In expression, particularly eukaryotic expression, one will typically include a poly adenylation signal to effect proper poly adenylation of the transcript.
  • the nature of the polyadenylation signal is not believed to be crucial to the successful practice of the invention, and any such sequence may be employed.
  • Preferred embodiments include the SV40 polyadenylation signal or the bovine growth hormone polyadenylation signal, both of which are convenient and known to function well in various target cells. Polyadenylation may increase the stability of the transcript or may facilitate cytoplasmic transport.
  • cells containing a nucleic acid construct of the present invention may be identified in vitro or in vivo by including a marker in the expression vector.
  • markers would confer an identifiable change to the cell permitting easy identification of cells containing the expression vector.
  • a selectable marker is one that confers a property that allows for selection.
  • a positive selectable marker is one in which the presence of the marker allows for its selection, while a negative selectable marker is one in which its presence prevents its selection.
  • An example of a positive selectable marker is a drug resistance marker.
  • a drug selection marker aids in the cloning and identification of transformants
  • genes that confer resistance to neomycin, puromycin, hygromycin, DHFR, GPT, zeocin and histidinol are useful selectable markers.
  • markers conferring a phenotype that allows for the discrimination of transformants based on the implementation of conditions other types of markers including screenable markers such as GFP, whose basis is colorimetric analysis, are also contemplated.
  • screenable enzymes such as herpes simplex virus thymidine kinase (tk) or chloramphenicol acetyltransferase (CAT) may be utilized.
  • FACS fluorescence activated cell sorting
  • the vector is introduced to the initially infected cell by suitable methods.
  • Such methods for nucleic acid delivery for transformation of an organelle, a cell, a tissue or an organism for use with the current invention are believed to include virtually any method by which a nucleic acid (e.g., HSV vector) can be introduced into an organelle, a cell, a tissue or an organism, as described herein or as would be known to one of ordinary skill in the art.
  • Non-limiting exemplary methods include: direct delivery of DNA by ex vivo transfection; injection (U.S. Pat. Nos.
  • composition can also be delivered to a cell in a mammal by administering it systemically, such as intravenously, in a pharmaceutically acceptable excipient.
  • a nucleic acid may be delivered to an organelle, a cell, a tissue or an organism via one or more injections (i.e., a needle injection), such as, for example, subcutaneously, intradermally, intramuscularly, intravenously, intraperitoneally, etc.
  • injections i.e., a needle injection
  • Methods of injection are well known to those of ordinary skill in the art (e g., injection of a composition comprising a saline solution).
  • Further embodiments of the present invention include the introduction of a nucleic acid by direct microinjection. The amount of composition of the present invention used may vary upon the nature of the cell, tissue or organism affected.
  • a nucleic acid is introduced into an organelle, a cell, a tissue or an organism via electroporation.
  • Electroporation involves the exposure of a suspension of cells and DNA to a high voltage electric discharge.
  • certain cell wall degrading enzymes such as pectin degrading enzymes, are employed to render the target recipient cells more susceptible to transformation by electroporation than untreated cells (U.S. Pat. No. 5,384,253).
  • recipient cells can be made more susceptible to transformation by mechanical wounding.
  • a composition as described herein may be entrapped in a lipid complex such as, for example, a liposome.
  • Liposomes are vesicular structures characterized by a phospholipid bilayer membrane and an inner aqueous medium. Multilamellar liposomes have multiple lipid layers separated by aqueous medium. They form spontaneously when phospholipids are suspended in an excess of aqueous solution. The lipid components undergo self rearrangement before the formation of closed structures and entrap water and dissolved solutes between the lipid bilayers.
  • a liposome may be complexed with a hemagglutinatin virus (HVJ). This has been shown to facilitate fusion with the cell membrane and promote cell entry of liposome encapsulated DNA (Kaneda et al., (1989) Science 20; 243(4889):375-8).
  • a liposome may be complexed or employed in conjunction with nuclear non histone chromosomal proteins (HMG1) (Kato et al., (1991) J Biol Chem. (1991) February 25; 266(6):3361 -4).
  • HMG1 nuclear non histone chromosomal proteins
  • a liposome may be complexed or employed in conjunction with both HVJ and HMG 1.
  • a delivery vehicle may comprise a ligand and a liposome.
  • a nucleic acid may be delivered to a target cell via receptor mediated delivery vehicles.
  • This approach takes advantage of the selective uptake of macromolecules by receptor mediated endocytosis.
  • this delivery method adds another degree of specificity to the present invention.
  • the receptor mediated gene targeting vehicle comprises a receptor specific ligand and a nucleic acid binding agent.
  • Other embodiments comprise a receptor specific ligand to which the nucleic acid to be delivered has been operatively attached.
  • ligands have been used for receptor mediated gene transfer including the epidermal growth factor (EGF), which has been used to deliver genes to squamous carcinoma cells as described in European Patent No. EPO 0 273 085.
  • a nucleic acid delivery vehicle component of a cell specific nucleic acid targeting vehicle may comprise a specific binding ligand in combination with a liposome.
  • the nucleic acid(s) to be delivered are housed within the liposome and the specific binding ligand is functionally incorporated into the liposome membrane. The liposome will thus specifically bind to the receptor(s) of a target cell and deliver the contents to a cell.
  • the nucleic acid delivery vehicle component of a targeted delivery vehicle may be a liposome itself, which will preferably comprise one or more lipids or glycoproteins that direct cell specific binding.
  • lipids or glycoproteins that direct cell specific binding.
  • lactosyl ceramide a galactose terminal asialganglioside
  • tissue specific transforming constructs of the present invention can be specifically delivered into a target cell in a similar manner.
  • Microprojectile bombardment techniques can be used to introduce a nucleic acid into at least one, organelle, cell, tissue or organism (U.S. Pat. No. 5,550,318; U.S. Pat. No. 5,538,880; U.S Pat. No. 5,610,042; and PCT Application No. WO 94/09699). This method depends on the ability to accelerate microprojectiles that are either coated with DNA or contain DNA, to a high velocity allowing them to pierce cell membranes and enter cells without killing them.
  • the microprojectiles may be comprised of any biologically inert substance, such as tungsten, platinum, or gold. For the bombardment, cells in suspension are concentrated on fdters or solid culture medium.
  • immature embryos or other target cells may be arranged on solid culture medium.
  • the cells to be bombarded are positioned at an appropriate distance below the microprojectile bombardment device on a stopping plate.
  • microprojectile bombardment techniques useful for practice with the current invention will be known to persons of skill in the art.
  • the terms “cell,” “cell line,” and “cell culture” may be used interchangeably. All of these terms also include their progeny, which is any and all subsequent generations. It is understood that all progeny may not be identical due to deliberate or inadvertent mutations.
  • “host cell” refers to a prokaryotic or eukaryotic cell, and it includes any transformable organism that is capable of replicating a vector and/or expressing a heterologous gene encoded by a vector. A host cell can, and has been, used as a recipient for vectors.
  • a host cell may be “transfected” or “transformed,” which refers to a process by which exogenous nucleic acid is transferred or introduced into the host cell.
  • a transformed cell includes the primary subject cell and its progeny.
  • the terms “engineered” and “recombinant” cells or host cells are intended to refer to a cell into which an exogenous nucleic acid sequence, such as, for example, a vector, has been introduced. Therefore, recombinant cells are distinguishable from naturally occurring cells that do not contain a recombinantly introduced nucleic acid.
  • a tissue may comprise a host cell or cells to be transformed with a cell membrane fusiongenerating HSV-2 mutant.
  • the tissue may be part or separated from an organism.
  • a tissue may comprise, but is not limited to, adipocytes, alveolar, ameloblasts, neural, basal cells, blood (e.g., lymphocytes), blood vessel, bone, bone marrow, glial cell, breast, cartilage, cervix, colon, cornea, embryonic, endometrium, endothelial, epithelial, esophagus, facia, fibroblast, follicular, ganglion cells, glial cells, goblet cells, kidney, liver, lung, lymph node, muscle, neuron, ovaries, pancreas, peripheral blood, prostate, skin, small intestine, spleen, stem cell, stomach, and testes.
  • the host cell or tissue may be comprised in at least one organism.
  • the organism may be, but is not limited to, a prokaryote (e.g., a eubacteria, an archaea) or a eukaryote, as would be understood by one of ordinary skill in the art.
  • a prokaryote e.g., a eubacteria, an archaea
  • a eukaryote e.g., a eukaryote
  • Numerous cell lines and cultures are available for use as a host cell, and are commercially available through organizations such as the American Type Culture Collection (ATCC).
  • ATCC American Type Culture Collection
  • An appropriate host can be determined by one of skill in the art based on the vector backbone and the desired result.
  • Exemplary non-limiting cell types available for vector replication and/or expression include bacteria, such as E. coli (e.g., E.
  • coli strains RR1, LE392, B, X 1776 (ATCC No. 31537), W3110, F, lambda, DH5a, JM109, and KC8); bacilli e.g., Bacillus subtilise other enterobacteriaceae e.g., Salmonella typhimurium, Serratia marcescens. as well as a number of commercially available bacterial hosts and competent cells such as SURE® Competent Cells and SOLOP ACKTM Gold Cells (STRATAGENE®, La Jolla, Calif).
  • eukaryotic host cells for replication and/or expression of a vector include, HeLa, NIH3T3, Jurkat, 293, Cos, CHO, Saos, and PCI2.
  • Some vectors may employ control sequences that allow it to be replicated and/or expressed in both prokaryotic and eukaryotic cells.
  • control sequences that allow it to be replicated and/or expressed in both prokaryotic and eukaryotic cells.
  • One of skill in the art would further understand the conditions under which to incubate all of the above described host cells to maintain them and to permit replication of a vector. Also understood and known are techniques and conditions that would allow large-scale production of vectors, as well as production of the nucleic acids encoded by vectors and their cognate polypeptides, proteins, or peptides.
  • the transgene can be inserted into the virus through homologous recombination. Typically, this is done by co-transfecting the plasmid DNA containing the transgene with purified HSV (e.g., HSV-2) genomic DNA into Vero cells using Lipofectamine. The recombinant virus is then identified (typically by screening the virus plaques for the presence of a selectable marker) and selecting plaques containing the transgene. The selected recombinant virus is then characterized in vitro to confirm that the transgene has been correctly inserted into the HSV genome.
  • HSV e.g., HSV-2
  • viral stocks can be prepared as follows. Vero cells are grown in 10% fetal bovine serum (FBS) and infected with 0.01 plaque forming units (pfu) per cell. Viruses are then harvested from the cells 2 days later by repeated freezing and thawing and sonication. The harvested virus is then purified as described (Nakamori, et al., (2003) Clinical Cancer Res. 9(7):2727-2733). The purified virus is then titered, aliquoted and stored at -80° C. until use.
  • FBS fetal bovine serum
  • pfu plaque forming units
  • Protein expression systems may be utilized in the generation of DNA vector compositions of the present invention for example, to express the polypeptide encoded by the transgene for functional studies. Numerous expression systems exist that comprise at least a part or all of the compositions discussed above. Prokaryote- and/or eukaryote-based systems can be employed for use with the present invention to produce nucleic acid sequences, or their cognate polypeptides, proteins and peptides. Many such systems are commercially and widely available. [0099] The insect cell/baculovirus system can produce a high level of protein expression of a heterologous nucleic acid segment, such as described in U.S. Pat. Nos. 5,871,986 and 4,879,236 and is commercially available (e.g., CLONTECH, Inc. Mountain View, Calif).
  • an inducible mammalian expression system which involves a synthetic ecdysone-inducible receptor, or a pET expression system, or an 77 coli expression system (STRATAGENE, LaJolla, Calif.);
  • a tetracycline-regulated expression system an inducible mammalian expression system that uses the full-length CMV promoter or a yeast expression system designed for high-level production of recombinant proteins in the methylotrophic yeast Pichia methanolica (INVITROGEN, Carlsbad, Calif).
  • proteins, polypeptides or peptides produced by the methods of the invention may be “overexpressed”, i.e., expressed in increased levels relative to its natural expression in cells.
  • overexpression may be assessed by a variety of methods, including radio-labeling and/or protein purification.
  • simple and direct methods are preferred, for example, those involving SDS/PAGE and protein staining or western blotting, followed by quantitative analysis, such as densitometric scanning of the resultant gel or blot.
  • a specific increase in the level of the recombinant protein, polypeptide or peptide in comparison to the level in natural cells is indicative of overexpression, as is a relative abundance of the specific protein, polypeptides or peptides in relation to the other proteins produced by the host cell and, e.g., visible on a gel.
  • compositions of the present invention can be administered as a pharmaceutical composition comprising the modified HSV-based vectors containing one or more copies of therapeutic genes, as described herein.
  • the compositions of the present invention include classic pharmaceutical preparations.
  • the compositions of the present invention can be administered as pharmacological agents by dissolving or dispersing the composition in a pharmaceutically acceptable carrier or aqueous medium.
  • the use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the compositions of the invention, its use in a therapeutic composition is contemplated.
  • Supplementary active ingredients such as other anti-disease agents, can also be incorporated into the pharmaceutical composition.
  • Administration of the composition will be via any common route so long as the target cell is available via that route.
  • exemplary administration routes include oral, nasal, buccal, rectal, vaginal or topical.
  • administration may be by orthotopic, intradermal, subcutaneous, intramuscular, intraperitoneal, intravenous, or direct intratumoral injection.
  • the pharmaceutical formulations, dosages and routes of administration for the compositions of the present invention are described herein.
  • Admini straction can be by systemic administration or by intracerebroventricular or intraperitoneal injection.
  • composition or HSV vector of the present invention can be prepared as a pharmacologically acceptable formulation.
  • the composition or vector is mixed with an excipient which is pharmaceutically acceptable and compatible with the virus.
  • excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof.
  • the preparation may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH-buffering agents, adjuvants or immunopotentiators, which enhance the effectiveness of the viral mutant (See, Remington's Pharmaceutical Sciences, Gennaro, A. R.
  • a typical pharmaceutically acceptable carrier for injection purposes may comprise from 50 mg up to about 100 mg of human serum albumin per milliliter of phosphate buffered saline.
  • Additional non-limiting exemplary non-aqueous solvents suitable for use in the formulation of a pharmacologically acceptable composition include propylene glycol, polyethylene glycol, vegetable oil, sesame oil, peanut oil and injectable organic esters such as ethyloleate.
  • Exemplary non-limiting aqueous carriers include water, aqueous solutions, saline solutions, parenteral vehicles such as sodium chloride, Ringer's dextrose, etc.
  • Intravenous vehicles include fluid and nutrient replenishers. Determining the pH and exact concentration of the various components of the pharmaceutical composition is routine and within the knowledge of one of ordinary skill in the art (See Goodman and Gilman's The Pharmacological Basis for Therapeutics, Gilman, A. G. et al., eds., Pergamon Press, pub., 8th ed., 1990).
  • Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various other sterile ingredients as required and described above.
  • dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients as described above.
  • CED convection-enhanced delivery
  • CED convection-enhanced delivery
  • Tn contrast to techniques of drug delivery that depend on diffusion to achieve adequate drug distribution, such as carmustine- impregnated biodegradable polymers, with CED it is possible to distribute drugs homogeneously over potentially large volumes of brain, irrespective of the molecular size of the therapeutic agent. As such it is an ideal technique for the administration of viral vector- mediated gene therapy to the brain of patients.
  • the HSV-based gene delivery vectors may be a composition that further comprises cerebrospinal fluid (CSF), especially artificial cerebrospinal fluid.
  • CSF cerebrospinal fluid
  • Artificial cerebrospinal fluid is well known in the art and is a fluid which mimics natural CSF, particularly in terms of its salt contents.
  • the composition comprises NaCl at a similar concentration to that found in natural CSF, that is to say the concentration is preferably within 15%, more preferably within 10% of the concentration in natural CSF.
  • the composition comprises NaHCCh at a similar concentration to that found in natural CSF, that is to say the concentration is preferably within 1 %, more preferably within 10% of the concentration in natural CSF.
  • the composition comprises KC1 at a similar concentration to that found in natural CSF, that is to say the concentration is preferably within 15%, more preferably within 10% of the concentration in natural CSF.
  • the composition comprises NaHzPC at a similar concentration to that found in natural CSF, that is to say the concentration is preferably within 15%, more preferably within 10% of the concentration in natural CSF.
  • the composition comprises MgCh at a similar concentration to that found in natural CSF, that is to say the concentration is preferably within 15%, more preferably within 10% of the concentration in natural CSF.
  • the composition comprises glucose at a similar concentration to that found in natural CSF, that is to say the concentration is preferably within 15%, more preferably within 10% of the concentration in natural CSF.
  • the artificial CSF may omit glucose, so as to reduce the likelihood of bacterial growth in any catheter used to administer the composition to a subject.
  • compositions of this invention may also comprise any pharmaceutically acceptable carrier, adjuvant or vehicle.
  • Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions include, but are not limited to, ion exchangers, alumina, aluminium stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulphate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol.
  • compositions of this invention may be administered by any appropriate route, but are preferably administered via injection, especially via a neurocatheter, in particular by convection enhanced delivery.
  • the pharmaceutical compositions may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles.
  • the mutant viral composition may be delivered by any route that provides access to the target tissue.
  • routes of administration may include oral, nasal, buccal, rectal, vaginal topical, or by injection (including orthotopic, intradermal, subcutaneous, intramuscular, intraperitoneal, intravenous, or intracerebroventricular injection).
  • the viral mutant would be prepared as an injectable, either as a liquid solution or a suspension; a solid form suitable for solution in, or suspension in, liquid prior to injection may also be prepared. The preparation also may be emulsified.
  • the pharmaceutical compositions may be in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension.
  • This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3 -butanediol.
  • suitable vehicles and solvents that may be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant such as Ph. Helv or a similar alcohol.
  • aqueous solution for parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
  • sterile aqueous media that can be employed will be known to those of skill in the art in light of the present disclosure.
  • one dosage could be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermolysis fluid or injected at the proposed site of infusion, (see for example, “Remington's Pharmaceutical Sciences” 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.
  • the amount of viral vector delivered will depend on several factors including number of treatments, subject to be treated, capacity of the subjects immune system to synthesize anti-viral antibodies, the target tissue to be destroyed, and the degree of protection desired.
  • the precise amount of viral composition to be administered depends on the judgment of the practitioner and is peculiar to each individual.
  • suitable dosage ranges from 10 5 plaque forming units (pfu) to 10 10 pfu.
  • the dosage of viral DNA may be about 10’, 10 6 , 10 7 , 10 8 , 10 9 , up to and including 10 10 pfu.
  • non-viral DNA vector can also be prepared as a sterile powder for the preparation of pharmacologically acceptable sterile solutions.
  • Typical methods for preparation of sterile powder include vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • non-viral vectors for the transfer of a polynucleotide of the present invention into a mammalian cell. These include calcium phosphate precipitation, DEAE-dextran, electroporation, direct microinjection, DNA-loaded liposomes and lipofectamine-DNA complexes, cell sonication, gene bombardment using high velocity microprojectiles, and receptor-mediated transfection as discussed previously. Some of these techniques may be successfully adapted for in vivo or ex vivo use.
  • the expression vector may simply consist of naked recombinant DNA or plasmids comprising the polynucleotide. Transfer of the construct may be performed by any of the methods mentioned herein which physically or chemically permeabilize the cell membrane. This is particularly applicable for transfer in vitro, but it may be applied to in vivo use as well.
  • the delivery vehicle may comprise a ligand and a liposome.
  • a ligand for example, Nicolau et al., employed lactosyl -ceramide, a galactose-terminal asi al ganglioside, incorporated into liposomes and observed an increase in the uptake of the insulin gene by hepatocytes (Nicolau et al., (1987) Methods Enzymol. 149:157-76).
  • a nucleic acid encoding a particular gene also may be specifically delivered into a cell type by any number of receptor-ligand systems with or without liposomes.
  • epidermal growth factor may be used as the receptor for mediated delivery of a nucleic acid into cells that exhibit upregulation of EGF receptor (as described in European Patent No. EP 0 273 085) and mannose can be used to target the mannose receptor on liver cells.
  • DNA transfer may more easily be performed under ex vivo conditions.
  • Ex vivo gene therapy refers to the isolation of cells from an animal, the delivery of a nucleic acid into the cells in vitro, and then the return of the modified cells back into an animal. This may involve the surgical removal of tissue/organs from an animal or the primary culture of cells and tissue.
  • the dosage may vary from between about 10 3 pfu/kg body weight to about 10 8 pfu/kg body weight. In certain embodiments, the dosage may be from about 10 3 , 10 4 , 10 5 , 10 6 , 10 7 , up to and including 10 8 pfu/kg body weight. Of course, this dosage amount may be adjusted upward or downward, as is routinely done in such treatment protocols, depending on the results of the initial clinical trials and the needs of a particular patient.
  • Yet another embodiment is a method of treating a disease in a patient in need thereof comprising administering to the patient a composition described herein or a non-replicating HSV-based vector described herein.
  • the disease or disorder can be a neurological disease or disorder.
  • the disease or disorder is not an oncologic disease or disorder (e.g., the disease or disorder is not a cancer).
  • the composition or HSV-based vector can be systemically, intramuscularly, intrademally, subcutaneously, or parenterally administered or administered by intracerebroventricular or intraperitoneal injection. Tn one embodiment, the patient has been exposed to or vaccinated against HSV-1 and/or HSV-2, or has HSV-1 and/or
  • Yet another embodiment is a method of vaccinating a patient against a malignant or infectious disease comprising administering to the patient a composition described herein or a non-replicating HSV-based vector described herein.
  • the transgene is one useful for vaccinating a patient.
  • Gene therapy can also be used in conjunction with the compositions and methods described herein as a combination therapy for the treatment of a disease or disorder.
  • Gene therapy as a combination treatment relies on the delivery and expression of a therapeutic gene, separate from the HSV vector described herein.
  • the gene therapy can be administered either before, after, or at the same time as the HSV vectordescribed herein.
  • exemplary non-limiting targets of gene therapy include immunomodulatory agents, agents that affect the up regulation of cell surface receptors and GAP junctions, cytostatic and differentiation agents, or inhibitors of cell adhesion.
  • Hormonal therapy may also be used in conjunction with the present invention.
  • the use of hormones may be employed in the treatment of various diseases to lower the level or block the effects of certain hormones such as testosterone or estrogen. Examples
  • FusOn-H2 was constructed as described in Example 1 of U.S. Patent No. 10,039,796. To systemically mutate the majority of the neutralizing epitopes on both gB and gD, as well as to enhance the complement antagonizing capability of the gC, FusOn-H2 was subjected to a series of selection in the presence of anti-HSV-2 sera. FusOn-H2 was initially subjected to the selection in cell culture in the presence of a mixture of serum collected from 5 rats that had been vaccinated with HSV and had high anti-HSV antibodies in blood.
  • HSV-2 antibodies was added into the rat sera and continued the selection.
  • HSV encodes several glycoproteins that are assembled on the surface of viral envelope. They include glycoprotein C (gC), gB, gD, gH and gL. Each of them can serve as a candidate molecule for incorporating the extracellular domain (ECD) of murine CD47 (mCD47) so that it may be engrafted to the surface of the virus envelope.
  • Glycoprotein C (gC) was chosen here, as unlike other glycoproteins mentioned, it is not essential for virus infectivity. As such, modifying it for incorporating mCD47 would not run the risk of altering the natural tropism of the oncolytic virus.
  • the ECD of mCD47 (aa 19-141) (SEQ ID NO: 1) (shown in the table below) was initially inserted into the N-terminus of gC to create the chimeric form of gC (cgC), and its expression is driven by CMV IE promoter.
  • the sequences of the full length murine CD47 (SEQ ID NO:2) and human CD47 (SEQ ID NO:4) are provided in the table below.
  • a HA (hemagglutinin) tag was included in cgC to allow the chimeric molecule to be conveniently detected.
  • cgC was linked to another gene cassette that contains the EGFP-luciferase gene. These two gene cassettes were inserted together into the backbone of FusOn-H3, which was derived from a HSV-2 based oncolytic virus (FusOn-H2) by deleting the GFP gene from the virus. FusOn-H2 was constructed by deleting and replacing the N-terminal region of the ICP10 gene with GFP to render it the ability to selectively replicate in and kill tumor cells.
  • the recombinant virus was identified by picking up GFP positive plaques. Each individually picked virus was enriched to homogenous GFP positivity through multiple rounds of plaque purification. The newly generated virus is designated FusOn-CD47-Luc (FIG. 2A).
  • a control virus was also constructed, in which only the EGFP-Luc gene cassette alone was inserted into the backbone of Fus0n-H3, FusOn-Luc (FIG. 2B). All the selected viruses maintain the fusogenic property of the parental Fus0n-H2.
  • Mouse splenocytes were used as the source of fresh phagocytes as spleen is the largest unit of the mononuclear phagocyte system. Vero cells were infected with FusOn-CD47- Luc or FusOn- Luc with or without the presence of mouse splenocytes. Cells were collected 48 h later for quantitative measurement of virus yield by plaque assay. The results in FIG. 3B showed that, in the wells without splenocytes, both FusOn- CD47-Luc and FusOn-Luc replicated well and the virus yield was similar in these two wells. However, in the wells with splenocytes, FusOn-Luc yield was significantly reduced while the replication of FusOn-CD47- Luc was only marginally affected. These results indicate that the presence of mCD47 ECD on viral particles enable the virus with the ability to resist the impact from macrophages and possibly some other immune cells during virus infection.
  • CD26 murine colon cancer cells were implanted to the right flank of immunocompetent Balb/c mice. Once tumors reached the approximate size of 8 mm in diameter, we systemically injected 2 x 106 pfu of either FusOn-CD47- Luc or FusOn-Luc to each mouse. Mice were monitored for luciferase activity by IVIS Spectrum System starting on day 2 and then on a daily basis until total disappearance of the signal. The results in FIG. 4 show that, at day 2 after virus administration, the imaging signal from FusOn- CD47-Luc was approximately one and a half log stronger than that from FusOn-Luc.
  • FusOn-CD47-Luc is also more superior than FusOn-Luc for systemic delivery in other tumor models, the above experiment was repeated, but in mice bearing tumors at the right flank established from implantation of 4T1 murine mammary tumor cells, in which FusOn-H2 was found to be able to grow moderately. Additionally, 4T1 tumor cells secrete macrophage colony stimulating factor (M-CSF) and granulocyte colony stimulating factor (G- CSF), which can enhance macrophage infdtration and phagocytosis.
  • M-CSF macrophage colony stimulating factor
  • G- CSF granulocyte colony stimulating factor
  • FusOn-CD47 was first subjected to 7 rounds of section with the rat sera and 17 rounds of section with the rat sera plus the human serum.
  • the anti-HSV sera mixture was used at different dilutions to incubate with the indicated viruses, after which the virus infectivity was determined.
  • the results in FIG. 6 show that, under this stringent neutralizing condition (containing a mixture of antiviral sera from multiple individuals), the selected virus can still produce a significant number of plaques while the unselected virus did not produce any plaque until the sera mixture was diluted by 80-fold.
  • the data also showed the subsequent three more rounds of selection in the human sera mixtures have further enhanced the ability of the selected virus in their ability to resist the neutralizing effect. Also, the data showed that some of the picked viruses have a better capability than others in resisting the neutralization by the mixed human antiviral sera.
  • FusOn-CD47 was readily detected in the tumor tissue by the same delivery route and in the presence of anti-HSV immunity. Moreover, FusOn-CD47 persisted in the tumor tissues for almost eight days after reaching the tumor site despite the presence of antiviral immunity. CD47 unexpectedly assisted the oncolytic virus in escaping the neutralization effect by anti-HSV antibodies, contributing to the overall ability of FusOn-SD in escaping neutralizing antibodies for systemic delivery. Accordingly, FusOn-SD behaved the best in systemic delivery to the tumor site. FusOn-SD is thus useful in patients having HSV-1 and/or HSV-2 antibodies, such as those vaccinated against HSV-1 and/or HSV-2 or having HSV-1 and/or HSV-2.
  • FIG. 9A is a bar chart showing the absorbance of FusOn-H2, FusOn-SD, and PBS (negative control) after treatment with mouse anti-HSV-2 gE (1 : 1000 dilution) and HPR- conjugated rabbit anti-mouse IgG (1 :10,000 dilution). More specifically, in FIG. 9A, 1X10 6 pfu of viruses (the parental FusOn-H2 and FusOn-SD) were coated to 96-well plate for ELISA assay. Wells coated with PBS served as the negative control.
  • FIG. 9B is a western blot showing detection of gE for FusOn-SD and FusOn-H2. Proteins were subtracted from 1X10 6 pfu of viruses (FusOn-H2 and FusOn-SD) and were run on an acrylamide gel for western blot analysis.
  • FIG. 9C is a schematic illustration on the mechanism of NK cell recognition of HSV or HSV infected cells via gE.
  • the drawing shows that gE binds to IgG (either virus specific or non virus specific).
  • the CD 16a which is one the most important NK cell activation receptors, then binds to the Fc region of the IgG, leading to the activation of NK cells and the clearance of either viral particles or the virus infected cells. This leads to reduced oncolytic virus delivery as well as replication, hence, minimizing the therapeutic effect of virotherapy. Because FusOn-SD is not recognized by this mechanism, NK cells do not clear them out and the therapeutic efficacy of FusOn-SD persists. References
  • Herpes Simplex Virus Type 2 Is More Difficult to Neutralize by Antibodies Than Herpes Simplex Virus Type 1 .
  • the present disclosure includes the following embodiments numbered El through E39. This list of embodiments is presented as an exemplary list and the application is not limited to these embodiments.
  • HSV herpes simplex virus
  • the HSV vector comprises a transgene
  • the HSV vector has a membrane envelope comprising glycoproteins, wherein at least one of the glycoproteins comprises an extracellular CD47 domain inserted into the N-terminus of the glycoprotein.
  • E2 The HSV-based vector of embodiment El, wherein the HSV vector is an HSV-1 or HSV-2 vector.
  • HSV-based vector of embodiment El or E2 wherein the HSV-based vector is an HSV amplicon packaged into a viral particle
  • glycoprotein is selected from glycoprotein C, glycoprotein B, glycoprotein D, glycoprotein H, and glycoprotein L.
  • E5. The HSV-based vector of embodiment E4, wherein the glycoprotein is glycoprotein C.
  • E6 The HSV-based vector of any of the preceding embodiments, wherein the transgene is a therapeutic gene.
  • E7 The HSV-based vector of any of the preceding embodiments, wherein the extracellular CD47 domain is an extracellular human CD47 domain.
  • E8 A composition comprising the HSV-based vector of any of the preceding embodiments, wherein the HSV vector is prepared by passaging at least twice the HSV vector with immune sera having elevated levels of anti-HSV antibodies.
  • E10 The composition of embodiment E8 or E9, wherein the extracellular CD47 domain comprises amino acids 19-141 of murine CD47.
  • El 1 The composition of embodiment E8 or E9, wherein the extracellular CD47 domain is an extracellular human CD47 domain.
  • E12 The composition of any one of embodiments E8-E11, wherein the HSV-based vector is free or substantially free of gE.
  • E13 The composition of any one of embodiments E8-E12, wherein the immune sera is a mixture comprising rat sera and human sera that has elevated levels of anti-HSV antibodies.
  • E14 The composition of any one of embodiments E8-E13, wherein the HSV-based vector has been prepared by passaging at least two times an HSV vector in the presence of rat sera having an elevated level of anti-HSV antibodies followed by passaging at least two times in the presence of a mixture of rat sera and at least one human serum having an elevated level of anti-HSV antibodies.
  • a composition comprising a non-replicating herpes simplex virus (HSV) based gene delivery vector, wherein (i) the HSV-based vector comprises a transgene, and (ii) the HSV- based vector is prepared by passaging at least twice the HSV-based vector with immune sera having elevated levels of anti-HSV antibodies.
  • HSV herpes simplex virus
  • E16 The composition of embodiment El 5 wherein the HSV-based vector is an HSV-1 or HSV-2 vector.
  • E17 The composition of embodiment E15 or E16, wherein the passaging in the immune sera mutates neutralizing epitopes on glycoprotein B and glycoprotein D of the HSV- based vector.
  • E18 The composition of any one of embodiments E15-E17, wherein the HSV-based vector is free or substantially free of gE.
  • El 9 The composition of any one of embodiments El 5-E18, wherein the immune sera is a mixture comprising rat sera and human sera that has elevated levels of anti-HSV antibodies.
  • E20 The composition of any one of embodiments E15-E19, wherein the HSV-based vector has been prepared by passaging at least two times the ElSV-based vector in the presence of rat sera having an elevated level of anti-HSV antibodies followed by passaging at least two times in the presence of a mixture of rat sera and at least one human serum having an elevated level of anti-HSV antibodies.
  • E21 The composition of any one of embodiments E15-E20, wherein the transgene is a therapeutic gene.
  • E22 A method of preparing a composition comprising a non-replicating HSV-based vector comprising passaging at least twice an HSV-based vector comprising a transgene with immune sera that has elevated levels of anti-HSV antibodies.
  • E23 The method of embodiment E22, wherein the HSV-based vector is an HSV-1 or HSV-2 vector.
  • E24 The method of embodiment E22 or E23, wherein the HSV-based vector has a membrane envelope comprising glycoproteins, wherein at least one of the glycoproteins comprises an extracellular CD47 domain inserted into the N-terminus of a glycoprotein.
  • glycoprotein is selected from glycoprotein C, glycoprotein B, glycoprotein D, glycoprotein H, and glycoprotein L.
  • E26 The method of embodiment E25, wherein the glycoprotein is glycoprotein C.
  • E27 The method of any one of embodiments E22-E26, wherein the passaging in the immune sera mutates neutralizing epitopes on glycoprotein B and glycoprotein D of the HSV- based vector.
  • E28 The method of any one of embodiments E24-E27, wherein the extracellular domain comprises amino acids 19-141 of murine CD47.
  • E29 The method of any one of embodiments E24-E27, wherein the extracellular CD47 domain is an extracellular human CD47 domain.
  • E30 The method of any one of embodiments E24-E29, wherein the HSV-based vector is free or substantially free of gE.
  • E31 The method of any one of embodiments E22-E30, wherein the immune sera comprises mammalian anti-HSV antibodies.
  • E32 The method of any one of embodiments E22-E31, wherein the immune sera is a mixture comprising rat sera and human sera that has elevated levels of anti-HSV antibodies.
  • E33 The method of any one of embodiments E22-E32, wherein the method comprises passaging the HSV-based vector at least two times in the presence of rat sera having an elevated level of anti-HSV antibodies followed by passaging at least once in the presence of a mixture of rat sera and at least one human serum having an elevated level of anti-HSV antibodies.
  • E34 A method of treating a disease in a patient in need thereof comprising administering to the patient an HSV-based vector of any one of embodiments E1-E7 or a composition of any one of embodiments E8-E21.
  • E35 The method of embodiment E34, wherein the composition or HSV vector is systemically, intramuscularly, intrademally, or subcutaneously administered or administered by intracerebroventricular or intraperitoneal injection.
  • E36 The method of embodiment E34 or E35, wherein the composition comprises cerebrospinal fluid.
  • E37 The method of any one of embodiments E34-E36, wherein the disease is a neurological disease.
  • E38 The method of any one of embodiments E34-E37, wherein the patient has been exposed to or vaccinated against HSV-1 and/or HSV-2, or has HSV-1 and/or HSV-2.
  • E39 A method of vaccinating a patient against a malignant or infectious disease comprising administering to the patient an HSV-based vector of any one of embodiments E1-E7 or a composition of any one of embodiments E8-E21.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des vecteurs basés sur le virus de l'herpès simplex (HSV) pour administrer des transgènes (par exemple, un gène thérapeutique) qui sont plus résistants à la neutralisation, à la phagocytose et aux cellules NK par des systèmes immunitaires, et des procédés destinés à leur préparation et au traitement de troubles et de maladies (tels que ceux liés à l'expression génique) grâce à ceux-ci. Dans un mode de réalisation, les vecteurs HSV sont préparés par traitement dans des sérums immunitaires qui contiennent un niveau élevé d'anticorps anti-HSV. Les vecteurs HSV peuvent comprendre un domaine CD47 extracellulaire inséré dans l'extrémité N-terminale d'une glycoprotéine afin d'inhiber l'activité phagocytaire, et l'absence de gE pour échapper aux cellules NK.
EP23716131.0A 2022-03-16 2023-03-15 Système d'administration de gène hsv persistant Pending EP4493213A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263269440P 2022-03-16 2022-03-16
PCT/US2023/064459 WO2023178191A1 (fr) 2022-03-16 2023-03-15 Système d'administration de gène hsv persistant

Publications (1)

Publication Number Publication Date
EP4493213A1 true EP4493213A1 (fr) 2025-01-22

Family

ID=85979423

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23716131.0A Pending EP4493213A1 (fr) 2022-03-16 2023-03-15 Système d'administration de gène hsv persistant

Country Status (5)

Country Link
US (1) US20230295661A1 (fr)
EP (1) EP4493213A1 (fr)
CN (1) CN118647400A (fr)
CA (1) CA3242289A1 (fr)
WO (1) WO2023178191A1 (fr)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
EP0273085A1 (fr) 1986-12-29 1988-07-06 IntraCel Corporation Procédé pour faire entrer des acides nucléiques dans des cellules eucaryotes
US4952500A (en) 1988-02-01 1990-08-28 University Of Georgia Research Foundation, Inc. Cloning systems for Rhodococcus and related bacteria
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
WO1994000977A1 (fr) 1992-07-07 1994-01-20 Japan Tobacco Inc. Procede de transformation d'une monocotyledone
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
EP0652965A1 (fr) 1992-07-27 1995-05-17 Pioneer Hi-Bred International, Inc. Procede ameliore de transformation induite par agrobacterium de cellules de soja cultivees
DE4228457A1 (de) 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US20120301506A1 (en) 2010-11-23 2012-11-29 Xiaoliu Zhang Oncolytic Virus as an Inducer for Innate Antitumor Immunity
WO2007002373A2 (fr) 2005-06-23 2007-01-04 Baylor College Of Medicine Utilisation de l'herpes simplex virus type 2 mutant dans le traitement du cancer
WO2008030560A2 (fr) * 2006-09-08 2008-03-13 The Trustees Of The University Of Pennsyvania Vaccins contre le hsv-1 et le hsv-2 et méthodes d'utilisation
US10174341B2 (en) 2013-07-17 2019-01-08 University of Pittsburgh—of the Commonwealth System of Higher Education Non-toxic HSV vectors for efficient gene delivery applications and complementing cells for their production
US20180148711A1 (en) 2015-05-28 2018-05-31 Coda Biotherapeutics, Inc. Genome editing vectors
US20190267845A1 (en) 2018-02-27 2019-08-29 Chargedge, Inc. Systems and methods for high-power wireless power transfer with dual-qi compatability
EP4291216A1 (fr) * 2021-02-09 2023-12-20 University of Houston System Virus oncolytique pour administration systémique et les activités anti-tumorales améliorées

Also Published As

Publication number Publication date
WO2023178191A1 (fr) 2023-09-21
CA3242289A1 (fr) 2023-09-21
CN118647400A (zh) 2024-09-13
US20230295661A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
US10039796B2 (en) Mutant herpes simplex virus-2 for cancer therapy
JP5492418B2 (ja) ウイルス関連疾患を予防するためのウイルス遺伝子産物およびワクチン接種の方法
US7097843B2 (en) Immunogenic peptides from the HPV E7 protein
US6734173B1 (en) HSP DNA vaccines
KR102133887B1 (ko) 면역글로불린 Fc가 융합된 인터루킨-7 융합 단백질을 포함하는 사람 파필로마바이러스 유래 질환의 예방 또는 치료용 약학적 조성물
JP2005521398A (ja) 癌治療用の強力な腫瘍溶解性単純ヘルペスウイルス
EP1021202A1 (fr) Peptides immunogenes issus de la proteine hpv e7
US11666649B2 (en) Vectors and vaccine cells for immunity against Zika virus
US20240123004A1 (en) Oncolytic virus for systemic delivery and enhanced anti-tumor activities
KR20230005265A (ko) Sars-cov-2에 대한 백신 및 이의 제조
US20230295661A1 (en) Persistent hsv gene delivery system
US5833991A (en) Glycine-containing sequences conferring invisibility to the immune system
TW202317172A (zh) Tnfsf-l融合蛋白及其用途
US20150246086A1 (en) Use of Mutant Herpes Simplex Virus-2 for Cancer Therapy
CN116782917A (zh) 用于全身递送的溶瘤病毒及增强的抗肿瘤活性
AU724621B2 (en) Amplification of response from expressed recombinant protein
WO2023081348A1 (fr) Polythérapie herpesvirale pour le ciblage de cellules cancéreuses et de cellules stromales associées au cancer
WO2024140767A1 (fr) Molécule polynucléotidique pour la prévention ou le traitement de maladies liées à une infection par le vph
KR20190103792A (ko) Il-7을 포함하는 돼지열병바이러스의 치료 및 예방용 조성물
Deshpande Host-pathogen interaction in bovine respiratory disease:(1) DNA immunization against bovine herpesvirus-1.(2) Role of CD18 in Mannheimia haemolytica leukotoxin-induced cytolysis of bovine leukocytes
CA2244881A1 (fr) Amplification de la reponse d'une proteine de recombinaison exprimee

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20241002

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR